We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 79

Government seeks feedback on new drug safety initiatives
  • Stikeman Elliott LLP
  • Canada
  • May 6 2015

As previously reported, the Food and Drugs Act (the Act) has been substantively amended by Bill C-17, also known as Vanessa's Law; the Bill received


Competition Bureau sets out preliminary views on patent agreement settlement enforcement
  • Stikeman Elliott LLP
  • Canada
  • October 27 2014

On September 23, 2014, John Pecman, the Commissioner of Competition, delivered the keynote address at the George Mason University Pharma Conference


Bill C-17 (Vanessa’s Law) receives third reading
  • Stikeman Elliott LLP
  • Canada
  • October 24 2014

Bill C-17, An Act to Amend the Foods and Drugs Act (Vanessa's Law) has proceeded through the committee process without amendment and was read for a


British Columbia Court of Appeal overturns certification of pharmaceutical class action
  • Stikeman Elliott LLP
  • Canada
  • February 20 2015

In a decision released January 22, 2015, the B.C. Court of Appeal unanimously overturned an order certifying a class proceeding against the


CSA report on medical marijuana issuer finds disappointing disclosure deficiencies
  • Stikeman Elliott LLP
  • Canada
  • February 23 2015

The Canadian Securities Administrators today released the results of CSA staff's review of continuous disclosure by reporting issuers announcing


Health Canada releases guidance on “danger to human health or safety” posed by consumer products
  • Stikeman Elliott LLP
  • Canada
  • December 20 2013

Health Canada has released a guidance document on factors it will consider when determining whether a consumer product poses a "danger to human


Court of Appeal clarifies - for utility the promise of the patent must be "clear and unambiguous"
  • Stikeman Elliott LLP
  • Canada
  • August 21 2013

On July 24, 2013, the Federal Court of Appeal (FCA) issued its decision in Apotex Inc. v. Sanofi-Aventis, overturning a Federal Court decision


B.C. Court dismisses proposed class action against generic manufacturers of fentanyl patch
  • Stikeman Elliott LLP
  • Canada
  • July 8 2014

On June 20, 2014, Justice Bracken of the British Columbia Supreme Court dismissed a proposed class action against two generic manufacturers of


Health and environmental claims an ongoing bureau focus
  • Stikeman Elliott LLP
  • Canada
  • December 18 2007

Investigations and enforcement actions over marketing and advertising claims related to health products and services have been a significant part of the Bureau's recent fair-business-practices work


Conditions for a valid selection patent does not constitute an independent basis for attacking validity
  • Stikeman Elliott LLP
  • Canada
  • August 18 2010

Eli Lilly, the plaintiff in a patent infringement action, was successful in appealing a decision of the Federal Court which had found Eli Lilly’s Canadian Letters Patent No. 2,041,113 (the ‘113 Patent) relating to the medicine olanzapine (Zyprexa) invalid on the basis that it was not a proper selection patent